Versartis, Inc. (NASDAQ:VSAR) has received an average rating of “Buy” from the ten ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $26.29.

Several equities research analysts have recently issued reports on the company. BidaskClub lowered Versartis from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. Zacks Investment Research lowered Versartis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Canaccord Genuity set a $28.00 price objective on Versartis and gave the company a “buy” rating in a research note on Sunday, May 28th. Cantor Fitzgerald assumed coverage on Versartis in a research note on Thursday, May 4th. They issued an “overweight” rating and a $34.00 price objective for the company. Finally, Piper Jaffray Companies set a $26.00 price objective on Versartis and gave the company a “buy” rating in a research note on Tuesday, June 27th.

Versartis (NASDAQ:VSAR) opened at 16.55 on Friday. The firm has a 50-day moving average price of $17.84 and a 200-day moving average price of $17.95. Versartis has a 52 week low of $9.05 and a 52 week high of $24.00. The stock’s market capitalization is $588.82 million.

Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.20. Equities research analysts predict that Versartis will post ($3.29) EPS for the current fiscal year.

Several large investors have recently modified their holdings of VSAR. Schwab Charles Investment Management Inc. raised its stake in shares of Versartis by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 109,409 shares of the biopharmaceutical company’s stock worth $1,910,000 after buying an additional 627 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Versartis by 4.2% in the second quarter. Rhumbline Advisers now owns 35,388 shares of the biopharmaceutical company’s stock worth $618,000 after buying an additional 1,420 shares in the last quarter. Alps Advisors Inc. raised its stake in shares of Versartis by 6.2% in the second quarter. Alps Advisors Inc. now owns 31,780 shares of the biopharmaceutical company’s stock worth $555,000 after buying an additional 1,845 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Versartis by 46.3% in the first quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 3,001 shares in the last quarter. Finally, American International Group Inc. raised its stake in shares of Versartis by 20.7% in the first quarter. American International Group Inc. now owns 18,962 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 3,250 shares in the last quarter. 77.88% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/11/versartis-inc-vsar-given-average-rating-of-buy-by-brokerages.html.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Analyst Recommendations for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.